## Ute M Moll

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8095081/publications.pdf

Version: 2024-02-01

40 papers 8,320 citations

172457 29 h-index 289244 40 g-index

41 all docs

41 docs citations

41 times ranked

13843 citing authors

#	Article	IF	CITATIONS
1	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 2018, 25, 486-541.	11.2	4,036
2	The MDM2-p53 interaction. Molecular Cancer Research, 2003, 1, 1001-8.	3.4	621
3	Transcription-independent pro-apoptotic functions of p53. Current Opinion in Cell Biology, 2005, 17, 631-636.	5.4	430
4	p63 and p73: Roles in Development and Tumor Formation. Molecular Cancer Research, 2004, 2, 371-386.	3.4	401
5	î"Np73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is Up-regulated in Human Tumors. Journal of Experimental Medicine, 2002, 196, 765-780.	8.5	309
6	Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells. Molecular Cancer Research, 2011, 9, 577-588.	3.4	238
7	Targeting tumour-supportive cellular machineries in anticancer drug development. Nature Reviews Drug Discovery, 2014, 13, 179-196.	46.4	202
8	p63 and p73: roles in development and tumor formation. Molecular Cancer Research, 2004, 2, 371-86.	3.4	200
9	Nuclear and mitochondrial apoptotic pathways of p53. FEBS Letters, 2001, 493, 65-69.	2.8	195
10	Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion. Cancer Cell, 2018, 34, 298-314.e7.	16.8	162
11	Hypoxia death stimulus induces translocation of p53 protein to mitochondria. FEBS Letters, 2001, 488, 110-115.	2.8	153
12	TAp73 is a central transcriptional regulator of airway multiciliogenesis. Genes and Development, 2016, 30, 1300-1312.	5.9	112
13	Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3624-3629.	7.1	85
14	Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target. Cancers, 2018, 10, 188.	3.7	84
15	MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53. Molecular Cell, 2016, 61, 68-83.	9.7	82
16	DNA-PK, the DNA-activated protein kinase, is differentially expressed in normal and malignant human tissues. Oncogene, 1999, 18, 3114-3126.	5.9	79
17	p73 Suppresses Polyploidy and Aneuploidy in the Absence of Functional p53. Molecular Cell, 2007, 27, 647-659.	9.7	75
18	p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo. Cell Death and Disease, 2017, 8, e2661-e2661.	6.3	75

#	Article	IF	Citations
19	p53 $\hat{\Gamma}$ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E3287-96.	7.1	73
20	MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP. Molecular Cell, 2015, 59, 243-257.	9.7	70
21	Recommended Guidelines for Validation, Quality Control, and Reporting of <i>TP53</i> Variants in Clinical Practice. Cancer Research, 2017, 77, 1250-1260.	0.9	68
22	Non-oncogenic roles of TAp73: from multiciliogenesis to metabolism. Cell Death and Differentiation, 2018, 25, 144-153.	11.2	63
23	Mitochondrial p53 mediates a transcription-independent regulation of cell respiration and interacts with the mitochondrial Fâ,Fâ,€-ATP synthase. Cell Cycle, 2013, 12, 2781-2793.	2.6	59
24	Extraction of type-IV collagenase/gelatinase from plasma membranes of human cancer cells. International Journal of Cancer, 1990, 45, 1137-1142.	5.1	48
25	TAp73 is essential for germ cell adhesion and maturation in testis. Journal of Cell Biology, 2014, 204, 1173-1190.	5.2	46
26	A Novel In Vitro CypD-Mediated p53 Aggregation Assay Suggests a Model for Mitochondrial Permeability Transition by Chaperone Systems. Journal of Molecular Biology, 2016, 428, 4154-4167.	4.2	45
27	Role of p53 family members p73 and p63 in human hematological malignancies. Leukemia and Lymphoma, 2012, 53, 2116-2129.	1.3	40
28	Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice. Journal of Clinical Investigation, 2010, 120, 2070-2080.	8.2	39
29	Functional histology of the neuroendocrine thymus. Microscopy Research and Technique, 1997, 38, 300-310.	2.2	32
30	Tissue-specific roles of p73 in development and homeostasis. Journal of Cell Science, 2019, 132, .	2.0	29
31	Depleting stabilized GOF mutant p53 proteins by inhibiting molecular folding chaperones: a new promise in cancer therapy. Cell Death and Differentiation, 2017, 24, 3-5.	11.2	27
32	The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells. Frontiers in Oncology, 2021, 11, 642603.	2.8	25
33	usefulness. Commentary re: F. Koga et al., Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin. Cancer Res., 9: 5501-5507, 2003, and P. Puig et al., p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder Cancer. Clin. Cancer Res., 9: 5642-5651, 2003. Clinical	7.0	22
34	Cancer Research, 2003, 9, 5437-41.  Macrophage migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of antigenâ€presenting cells in skin. FASEB Journal, 2017, 31, 526-543.	0.5	21
35	Cortical hypoplasia and ventriculomegaly of p73â€deficient mice: Developmental and adult analysis. Journal of Comparative Neurology, 2014, 522, 2663-2679.	1.6	20
36	Cajalâ€Retzius neurons are required for the development of the human hippocampal fissure. Journal of Anatomy, 2019, 235, 569-589.	1.5	16

#	Article	IF	CITATION
37	Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner. Cell Death and Disease, 2017, 8, e2683-e2683.	6.3	13
38	Statin as anti-cancer therapy in autochthonous T-lymphomas expressing stabilized gain-of-function mutant p53 proteins. Cell Death and Disease, 2020, $11$ , 274.	6.3	12
39	Disrupting the p53-mdm2 interaction as a potential therapeutic modality. Drug Resistance Updates, 2000, 3, 217-221.	14.4	11
40	Corrigendum to: Hypoxia death stimulus induces translocation of p53 protein to mitochondria. FEBS Letters, 2001, 501, 97-98.	2.8	2